25^th Global Meet on
Cancer Research & Oncology

Ondrej Slaby is a Professor of Medical Biochemistry at the the 1st Faculty of Medicine at Charles University in Prague, Czech Republic. He works as Research Group Leader at the Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University (Brno, Czech Republic) and as a Scientific Secretary at the Masaryk Memorial Cancer Institute in Brno. Prof. Slaby has published extensively in the field of non-coding RNAs and solid cancer with special focus on their translational potential in diagnostics and as the therapeutic targets (h-index 31, Sum of the times cited without auto-citations > 3500. Since 2018, prof. Slaby is a chair of Czechoslovak Biological Society. In 2010 and 2012 received Award of Czech Society for Oncology, in 2016 an Award of Czech Medical Society and 2014 and 2016 Award for Medical Research of Czech Minister of Health, Novartis Discovery Award 2017.

Molecular Medicine, Cancer Therapy

Dr. Igor F. Tsigelny is an expert in structural biology, molecular modeling, bioinformatics, structure-based drug design and personalized cancer medicine. He published >200 articles, 4 scientific books and around 15 patents. The book Protein Structure Prediction: Bioinformatic Approach that he edited has been called The Bible of all current prediction techniques by BioPlanet Bioinformatics Forums. His computational study of molecular mechanisms of Parkinson's disease was included in the US Department of Energy publication Decade of Discovery where the best computational studies of the decade 1999 - 2009 have been described. He is a Professor in the UC San Diego and CSO of CureMatch Inc. (San Diego). Email: itsigeln@ucsd.edu

Structural Biology, Molecular Modeling, Bioinformatics, Cancer Medicine

Barbara Wollenberg Professor at University Hospital Schleswig-Holstein. She studied medicine at Saarland University in Saarbrücken and at LMU Munich, Germany. She got Heisenberg Fellowship from the German Research Foundation (DFG) at the Helmholtz Centre in Munich, Germany. Barbara Wollenberg worked as a C4 professor of otorhinolaryngology and head and neck surgery at the Lübeck Campus of the University Medical Centre Schleswig-Holstein, Germany. She worked Vice dean of the Faculty of Medicine at the University of Lübeck, Germany and Review board member of the German Research Foundation (DFG). She achieved many awards like Monika Kutzner Prize for cancer research from the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW), 2001, Anton von Troeltsch Prize from the German Society of Otorhinolaryngology, Head and Neck Surgery for "Immunological therapies for patients with cancers of the head and neck", 1999. Her main specialization is in the field of Biochemistry, immunology. Apart from this she is also an eminent Specialist in otorhinolaryngology and head and neck surgery, allergology, treatment of tumours using drugs, palliative medicine, ultrasound trainer.

Her main research interest is in the field Immune system responses to tumours and Development of vaccines.

William T. Beck, PhD, is University Distinguished Professor and former Head of the Department of Biopharmaceutical Sciences in the College of Pharmacy at the University of Illinois at Chicago. His research efforts have focused on understanding the molecular and genetic mechanisms of anticancer drug action and tumor cell resistance to anticancer drugs. His current research focuses on splicing factor genes and their involvement in cancer initiation, progression, and resistance to therapy, as well as their potential as novel therapeutic targets in ovarian, breast, and brain cancers.

cancer initiation, progression, and resistance to therapy

Dr. Alain L Fymat is a medical-physical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles). As invited/keynote speaker and member of organizing committees of international congresses and symposia, he has lectured extensively in the USA, Canada, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 32 medical-scientific Journals.

Dr. Fymat’s current research interests lie at the interface between science and medicine, particularly nanomedicine, nanobiotechnology, cancer/oncology, molecular/personal/precision medicine, human genetics/ epigenetics/ ecogenetics, neurodegenerative diseases, and pharmacogenomics. His most recent publications deal with nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders (epilepsy, Parkinson's and Alzheimer's diseases).

Dr Psyrri, Chief of Medical Oncology and Assistant Professor of Medicine, National Kapodistrian University of Athens Medical School, Attikon University Hospital, 2nd Dept. of Internal Medicine – Propaedeutic,Research Institute Athens, Greece. She earned her Medical Degree from Patras University School of Medicine, Rio, Patras, Greece in 1993, and her PhD from the University of Athens Medical School in 2007. Her work has been awarded several prizes and recognitions. She has published 125 articles in peer-reviewed journals and several book chapters.

Translational Research, Medical Oncology, Head and Neck Cancer

Barbara DeVivo has spent her entire career in marketing management serving various executive global roles from market analysis and research, business development product management and professional relations. Ms. DeVivo has also amassed a strong proficiency in all facets of marketing management, sharing both academic and professional experiences. Currently, Ms. DeVivo is a PhD student at the State University of New York at Albany- Rockefeller College of Public Affairs and Policy whose research is centered on Organizational Behavior Management in Healthcare. Additionally, she serves as President and Founder of Extended Marketing Services, a real estate and healthcare consulting company. Ms. DeVivo has also held the position of Adjunct Professor of Marketing at the University of Memphis as well as Union Graduate College and has taught Marketing, Advertising and Brand Promotions, Market Research, and Negotiations. Furthermore, she has held the position of Executive Director of Marketing at the University of Memphis managing the operations, strategy development and execution of all marketing activities for its business school. Prior to then, Ms. DeVivo served in the healthcare industry as Director of Professional Relations for Thermage and was responsible for managing the key physician opinion leaders for the company world-wide and creating global awareness of all clinical and professional activities conducted by physicians and the company. From 2005-2007, she served as Director of Marketing for RITA Medical where she lead the company’s drug eluting therapy efforts in the oncology market for the treatment of nonresectable metastatic liver, lung and kidney tumors, broke through and built the US market with a novel procedure and served the company through product management, business development and market analysis for emerging businesses. Prior to RITA, Ms. DeVivo worked for CR Bard managing the company’s brachytherapy oncology business for the treatment of prostate and breast cancer.

Healthcare Management and Organizational Management

Jawad Hamad, is a Professional pharmaceutical physician with a diversified operational and functional medical affairs experience in different MENA countries and different therapeutic areas, blended with Research experience and drug development from translational science, proof of concept, interventional and non-interventional cohorts. He has Professional Peer review experience in Pharmaceutical Compliance with a proven track record of successful planning, integration and execution of strategies cascaded within the organization.

Oncology, Clinical Trials, Drug Development

Hiroshi Kobayashi received his Ph.D. in Biochemistry from University of Tokyo in 1974. After his postdoctoral training at Colorado University Medical Center, he started to study adaptation strategies of microorganisms to acidic environments at Chiba University in 1978. His research has been focused on mammalian cell functions under acidic conditions from 1996 at Graduate School of Pharmaceutical Sciences, Chiba University. His current challenge is to develop cancer chemotherapy specific to acidic nests. He retired in March 2012 and is now a professor emeritus at Chiba University. He works as an associate editor of International Immunopharmacology published by Elsevier B.V. from 2014.

cancer chemotherapy

Shalini Gupta is the Associate Professor, Department of Oral Pathology & Microbiology, King Georges Medical University, Lucknow, India. She had University Merit Scholarship and got fourteen Gold Medals. She has involved with various research projects & reviewer in various journals. She has written two books and published around 50 papers in reputed journals and serving as an editorial member of many reputed journals.

Clinical Trials Operations, Risk Based Monitoring, Medical Writing, PVG

Antonio Gomez-Munoz received his Ph.D in Biochemistry from the University of the Basque Country, Bilbao (Spain) in 1988. He achieved postdoctoral training at the University of Alberta in Edmonton (Canada) from 1988 to 1994. He then accepted a Research position at the Spanish Research Council (CSIC) from 1995 to 1996. From 1997 to 1998, he worked as Research Associate at the University of British Columbia (Vancouver, Canada). Since then, he has been working at the University of the Basque Country in Bilbao (Spain), where he is currently Professor of Biochemistry and Molecular Biology. He belongs to the Editorial Advisory Board of various scientific journals. Since 2001, he is a member of the International Advisory Committee of the Charleston Ceramide Conference, and since 2005, he is permanent Co-chair of the European Sphingolipid Club. His research interest is on the regulation of lipid metabolism and signalling, and in recent years he focused on the targeting of sphingolipid metabolites and enzymes with the aim of developing new strategies for prevention of disease.

Biochemistry, Molecular Biology, Oncology

Dr. Bhattacharjee did her B.Sc in Biotechnology from Bangalore University in 2006 and M.Sc in Applied Genetics from Bangalore University in 2008. She then moved to England to pursue her DPhil (Phd) in Biochemistry from Oxford University where she studied the role of Fml1 and its partner proteins Mhf1 and Mhf2 in promoting genome stability. She was awarded her DPhil in 2012. During her time at Oxford, she was also a tutor at Greene College, Oxford. In 2013, Dr. Bhattacharjee moved to Cold Spring Harbor Laboratory, New York.

Her work has focused on understanding the epigenetic regulation of DNA repair. She is also an academic tutor at the Watson School of Biological studies, the school for graduate studies at CSHL

I’m graduated from Capital Medical University in 2015 as the major of Medical Laboratory Tests (MLT). After finished the internship in Beijing Anzhen Hospital, I joined in Dept. Clinical Oncology, HKU as research in October 2015. In September 2017, I began my postgraduate study in the same laboratory with supervision of Prof. Dora Kwong and Prof. XY Guan. Our laboratory is focus on discovering novel cancer related genes and mir-RNAs in gastric cancer (GC), hepatocellular carcinomas (HCC), esophageal carcinomas (ESCC) and nasopharyngeal carcinoma (NPC). My current study is supported by Health and Medical Research Fund (No.04150826).

Clinical Oncology

I completed BSc (Hons) Biochemistry at Kwame Nkrumah University of Science and Technology (KNUST) in 2015. I then became a Teaching/Research Assistant at the Pathology Department of KNUST for one year before enrolling in MPhil. Chemical Pathology (Department of Molecular Medicine) in August 2016. I was a Graduate Assistant in the just ended 2017/2018 academic year (from September 1, 2017 to May 31, 2018). I am currently in the final stages of my project work titled “A Ten-year Review of Human Papillomavirus in Head and Neck Cancer at Komfo Anokye Teaching Hospital”. I also work as a Research Coordinator in a private Hospital during my spare time.

Cancer Research

Muhammad Sadeqi Nezhad is an Elite Medical Researcher in Iran majoring in Clinical Laboratory Sciences. His field of research are Oncology, Genetics and Molecular Biology. Currently he is involved in CRISPR/Cas Systems, Leukemia and CAR-T cell Studying.

Oncology, Genetics and Molecular Biology

I am Frank Adu and I was born in Ghana. I completed my undergraduate degree at the Kwame Nkrumah University of Science and Technology, Ghana where I pursued biochemistry. Currently, I am a masters student at the University of Chester, United Kingdom. I am studying MSc Biomedical Sciences. My research interest lies in the field of cancer. I believe with more research effective vaccines/therapeutics can be obtained to aid treatment of various human cancers.

Measuring the effect of SP600125 inhibition on other mitogen-activated protein kinase (MAPK) signaling components in U937 leukemic cell line